Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 17/20 | 0.73 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243957 | 0.90 | PYGL (0.73) | PYGLCYP51A1EGFR | |
| SCHEMBL6742819 | 0.89 | PYGL (0.78) | PYGLCYP51A1EGFR | |
| SCHEMBL2606872 | 0.87 | PYGL (0.54) | PYGLCYP51A1 | |
| Ingliforib SCHEMBL7239034 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL8739351 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL29388624 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL122709 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL13483321 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| SCHEMBL7244130 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL6705938 | 0.87 | PYGL (0.74) | PYGLCYP51A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | PYGL 1/4885CYP51A1 688/4885EGFR 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.